Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 12.98M P/E - EPS this Y 62.50% Ern Qtrly Grth -
Income -28.34M Forward P/E -0.19 EPS next Y 50.50% 50D Avg Chg -10.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -16.00%
Dividend N/A Price/Book 0.68 EPS next 5Y - 52W High Chg -77.00%
Recommedations 2.00 Quick Ratio 0.71 Shares Outstanding 22.71M 52W Low Chg 66.00%
Insider Own 1.81% ROA -73.35% Shares Float 21.96M Beta 2.26
Inst Own 3.05% ROE - Shares Shorted/Prior 341.65K/443.60K Price 1.00
Gross Margin - Profit Margin - Avg. Volume 51,474 Target Price 6.00
Oper. Margin - Earnings Date Aug 14 Volume 121,900 Change -2.91%
About Iterum Therapeutics plc

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics plc News
11/15/24 Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...
11/14/24 Iterum Therapeutics Reports Third Quarter 2024 Financial Results
11/11/24 Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
10/28/24 FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships
10/28/24 FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment
10/28/24 Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
10/25/24 Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
10/10/24 Iterum Therapeutics to Present Data at IDWeek 2024
10/09/24 Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
09/24/24 Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts
09/11/24 ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
09/10/24 Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
09/06/24 Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
08/16/24 When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable?
08/14/24 Iterum Therapeutics Reports Second Quarter 2024 Financial Results
08/07/24 Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
08/06/24 Iterum Therapeutics Announces Expiration and Results of Rights Offering
08/02/24 Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
07/22/24 Iterum Therapeutics Starts Rights Offering
07/22/24 Iterum Therapeutics Commences Rights Offering
ITRM Chatroom

User Image HaranBanjo Posted - 12 minutes ago

$ITRM honestly , I don't see why we should be afraid. we have been above the dollar for more than 10 sessions and there is enough money in the box, even if the pharmaceutical research is now over. There are hundreds of worse companies on Nasdaq and yet they manage to have compliance... I feel more than calm

User Image Klinsmann Posted - 1 hour ago

$ITRM I really don‘t understand that irrelevant discussion! 10$ stocks with around 500 million market cap (+x) don‘t trade on otc…

User Image WaynD01 Posted - 3 hours ago

$ITRM I have provided all the info needed in this situation and still pretending that you did not get and predicting that the price would go down. Looks like you read a very old like 4-5 years old issue and sold the shares and now wants it cheap. I cannot assure 100% that the price wont go down, but it is unlikely that it would be due to this non compliance. We have passed that big compliance test from our perspective and I hope the Nasdaq will honor even if that was achieved after their delisting notice.

User Image Steloc Posted - 4 hours ago

$ITRM this is very good sign. Only .02 cents down AH. Excellent shape. .10 to .25 tomorrow.

User Image gandolf63 Posted - 5 hours ago

$ITRM even if they dont qualify fully i believe they will get the extension till march. I’m thinking they have a deal or very near to it. NASDAQ will be all ears

User Image WaynD01 Posted - 5 hours ago

@Philippians4_4 Dude, What you posted is from 2020 and we are at the end of 2024 now. There was so much water under the bridge now. You need to read latest SEC filing . (We are in Nasdaq Capital market now, where you need only $35M market cap. Refer my earlier screen shot. $ITRM

User Image lily2932 Posted - 5 hours ago

$ITRM hi, you guys must understand, with new Secretory of health department Robert kennedy, it will be more difficult to get Fda approval in the next a few years. so cherish this undervalued stock. buy more as much as you can.

User Image WaynD01 Posted - 5 hours ago

$ITRM Just to clarify. Even though current compliance is on stockholder's equity requirement, We have achieved the alternate requirement with the MVLS as I posted early. So I guess NASDAQ hearing tomorrow will take account of it call it as in compliance.

User Image Keepitmoving Posted - 5 hours ago

$ITRM Been over $1 for more than 10 consecutive trading days. This is not non-compliant.

User Image WaynD01 Posted - 5 hours ago

$ITRM on 11/7 where we closed at the lowest must be at $35.62M

User Image WaynD01 Posted - 6 hours ago

$ITRM Most likely we will be continuing in Nasdaq . Also we have possibly regained the compliance already as our market cap is above $35M for the last 10 days as of today.

User Image look2theblue Posted - 6 hours ago

$ITRM So I gotta be honest, this makes me helluva lot nervous. We're out of listing compliance on both shareholder equity and marketcap? And looking at the current metrics we still appear out of compliance. The hearing is tomorrow? Yikes. If this gets delisted the company could be sold for pennies on the dollar out from under us shareholders? This sucks! Not sure how I missed that 8-k filing.

User Image tradewins100 Posted - 6 hours ago

$ITRM

User Image lily2932 Posted - 6 hours ago

$ITRM tomorrow $1.73-1.8

User Image lily2932 Posted - 6 hours ago

$ITRM

User Image fwank Posted - 6 hours ago

$ITRM there is no risk of delist. Not sure why this is even coming up.

User Image HawkII Posted - 9 hours ago

$ITRM Viewing this from a CEO position, I don’t think they even care if the stock is delisted, they are orchestrating a Buy out, a buyer is interested in the Drug, not the stock price.

User Image TROYTIPTON Posted - 9 hours ago

$ITRM

User Image WaynD01 Posted - 10 hours ago

$ITRM Short borrowing rate is going up every day. Yesterday it was 20% and today is at 25% .. May be an eventual squeeze with news?

User Image vic1torious Posted - 10 hours ago

$ITRM it would be ridiculous if they didn’t get an extension. After getting a monumental FDA approval. I’m not really worried about it

User Image gabyrig Posted - 11 hours ago

$ITRM Algo land. This is not financial advice, especially that my average is not what yours is... and I'm not into pumping or bashing but this is a good sign. I've been waiting for a while to see crap like this on low volume. The listing concerns need to be resolved still but I'll take these odds.

User Image gabyrig Posted - 11 hours ago

$ITRM All that matters is the print on the daily chart and what they want to communicate. We are not in control of this danse. That was a win 😂

User Image gandolf63 Posted - 11 hours ago

$ITRM by the close it almost seems like someone knows the extension will be granted

User Image FitzCatalyst Posted - 11 hours ago

$ITRM moving on up.

User Image stelov Posted - 11 hours ago

$ITRM Schwab $1.55 after hours Share Profile Market Cap: Micro Cap $41.82M Shares Outstanding 27.52M Shares held by Institutions 7.42% Enterprise Value $42.45M Short Interest Short Interest Table Percentage of Shares Outstanding 9.20 Number of Shares Short 2.53M Number of Shares - Previous Month 215.25K Short Interest Ratio (Days) 0.23 Short Interest Ratio - 1 Month Ago (Days) 1.15

User Image Immc Posted - 11 hours ago

$ITRM what just happened? It dropped from 1.62 to 1.55 instantly? Not even showing in my charts yet.

User Image gandolf63 Posted - 11 hours ago

$ITRM As previously disclosed, on April 3, 2024, the Listing Qualifications department of The Nasdaq Stock Market LLC ("Nasdaq") notified Iterum Therapeutics plc (the “Company”) that it did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5550(b) (the “Rule”); ai says: ”

User Image ThatGuy887 Posted - 11 hours ago

$ITRM So they present their case for extension tomorrow. Doesn't mean they'll get a response/answer tomorrow, correct? Tomorrow could be another 5-7% climb and I have np with that.

User Image beachbroke Posted - 11 hours ago

$ITRM

User Image StonkZombie Posted - 11 hours ago

$ITRM Finished over my average. Now I'm green thank you very much. Let's see what tomorrow brings.

Analyst Ratings
HC Wainwright & Co. Buy Aug 15, 24
HC Wainwright & Co. Buy Jun 21, 24
HC Wainwright & Co. Buy May 31, 24
HC Wainwright & Co. Buy May 14, 24
HC Wainwright & Co. Buy Apr 30, 24
HC Wainwright & Co. Buy Apr 1, 24
HC Wainwright & Co. Buy Mar 6, 24
HC Wainwright & Co. Buy Feb 7, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dunne Michael W. Director Director Dec 22 Buy 1.40 25,000 35,000 113,754 12/27/23
Dunne Michael W. Director Director Nov 22 Buy 2.0345 20,000 40,690 78,754 11/27/23
Fishman Corey N. Chief Executive Offi.. Chief Executive Officer Nov 20 Buy 1.5863 10,000 15,863 54,449 11/20/23
Hecht Beth Director Director Jun 15 Option 0.00 15,853 18,839 06/15/23
Dunne Michael W. Director Director Jun 15 Option 0.00 15,853 53,488 06/15/23
Chin Mark Director Director Jun 15 Option 0.00 15,853 18,306 06/15/23
Dunne Michael W. Director Director Apr 01 Option 0.00 1,299 37,635 06/05/23
HUNT RONALD Director Director Apr 01 Option 0.00 2,041 6,071 04/03/23
Ahrens Brenton Karl Director Director Sep 08 Sell 2.3 33,298 76,585 82,246 09/12/22
Dunne Michael W. Director Director Sep 07 Buy 2.22 10,000 22,200 35,576 09/09/22
Hecht Beth Director Director Jun 23 Option 0.00 36,798 44,805 06/24/22
Dunne Michael W. Director Director Mar 25 Option 0.00 10,494 346,849 03/29/22
Hecht Beth Director Director Mar 18 Option 0.00 7,642 8,007 03/22/22
Matthews Judith M. Chief Financial Offi.. Chief Financial Officer Mar 11 Sell 0.31 63,340 19,635 65,292 03/15/22